Brokerages Set Chemed Corp. (CHE) PT at $214.50

Shares of Chemed Corp. (NYSE:CHE) have been assigned an average recommendation of “Hold” from the six research firms that are presently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $214.50.

A number of brokerages have issued reports on CHE. Zacks Investment Research raised Chemed Corp. from a “hold” rating to a “buy” rating and set a $213.00 price target for the company in a report on Wednesday, August 23rd. BidaskClub downgraded Chemed Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Royal Bank Of Canada reissued a “hold” rating and issued a $209.00 price target on shares of Chemed Corp. in a report on Monday, July 31st. KeyCorp began coverage on Chemed Corp. in a report on Monday, August 28th. They issued a “sector weight” rating for the company. Finally, TheStreet downgraded Chemed Corp. from a “b+” rating to a “c+” rating in a report on Tuesday, July 25th.

In other news, insider Spencer S. Lee sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $197.46, for a total transaction of $197,460.00. Following the completion of the transaction, the insider now directly owns 37,809 shares of the company’s stock, valued at approximately $7,465,765.14. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Kevin J. Mcnamara sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, July 28th. The stock was sold at an average price of $201.16, for a total value of $3,017,400.00. Following the transaction, the insider now directly owns 173,801 shares of the company’s stock, valued at $34,961,809.16. The disclosure for this sale can be found here. Corporate insiders own 5.32% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. BNP Paribas Arbitrage SA raised its stake in shares of Chemed Corp. by 1.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 3,891 shares of the company’s stock worth $711,000 after buying an additional 39 shares during the period. Municipal Employees Retirement System of Michigan raised its stake in shares of Chemed Corp. by 1.1% during the 1st quarter. Municipal Employees Retirement System of Michigan now owns 3,700 shares of the company’s stock worth $676,000 after buying an additional 40 shares during the period. Kalos Management Inc. raised its stake in shares of Chemed Corp. by 0.7% during the 2nd quarter. Kalos Management Inc. now owns 6,521 shares of the company’s stock worth $1,333,000 after buying an additional 45 shares during the period. Capstone Asset Management Co. raised its stake in shares of Chemed Corp. by 2.7% during the 2nd quarter. Capstone Asset Management Co. now owns 1,857 shares of the company’s stock worth $380,000 after buying an additional 49 shares during the period. Finally, Nisa Investment Advisors LLC raised its stake in shares of Chemed Corp. by 0.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 11,600 shares of the company’s stock worth $2,373,000 after buying an additional 50 shares during the period. 96.96% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Brokerages Set Chemed Corp. (CHE) PT at $214.50” was originally reported by Week Herald and is owned by of Week Herald. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://weekherald.com/2017/09/17/brokerages-set-chemed-corp-che-pt-at-214-50.html.

Shares of Chemed Corp. (NYSE CHE) traded up 1.38% during trading on Thursday, hitting $195.88. 211,555 shares of the stock traded hands. The stock has a 50 day moving average of $193.71 and a 200 day moving average of $195.72. The firm has a market cap of $3.13 billion, a price-to-earnings ratio of 48.59 and a beta of 1.14. Chemed Corp. has a 52-week low of $132.92 and a 52-week high of $216.01.

Chemed Corp. (NYSE:CHE) last announced its quarterly earnings results on Tuesday, July 25th. The company reported $2.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.89 by $0.26. Chemed Corp. had a return on equity of 26.18% and a net margin of 4.16%. The company had revenue of $415.06 million during the quarter, compared to the consensus estimate of $407.56 million. During the same period in the previous year, the company posted $1.80 earnings per share. Chemed Corp.’s revenue for the quarter was up 6.3% on a year-over-year basis. Analysts expect that Chemed Corp. will post $8.21 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Monday, August 14th were paid a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 0.57%. This is an increase from Chemed Corp.’s previous quarterly dividend of $0.26. The ex-dividend date was Thursday, August 10th. Chemed Corp.’s dividend payout ratio is presently 28.07%.

About Chemed Corp.

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply